RESUMEN
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic inflammatory condition that significantly affects quality of life. Conventional treatments have had limited success. this study evaluates the safety and efficacy of Sphingosine 1-phosphate receptor modulators (S1PrMs) as a potential treatment for IBD. METHODS: We conducted a thorough search of published literature on PubMed, EMBASE, and Google Scholar from 2000 to 2023. The inclusion criteria were randomized controlled trials (RCTs) with a target population comprising of IBD patients receiving either S1PrMs or placebo and a comparison of the 2. The statistical analysis was conducted using RevMan (version 5.4). Forest plots presented the results as risk ratios (RR) with a 95% confidence interval. RESULTS: A total of 7 RCTs involving 2471 patients were included. The results were reported for both the induction and maintenance phases of treatment. in the induction phase, the intervention group proved to have a significantly higher incidence of histological remission (RRâ =â 2.67; 95% CI [1.97, 3.60]; Pâ <â .00001), endoscopic improvement (RRâ =â 2.06; 95% CI [1.66, 2.56]; Pâ <â .00001), clinical remission (RRâ =â 2.23; 95% CI [1.43, 3.46]; Pâ <â .0004) and clinical response (RRâ =â 1.37; 95% CI [1.01, 1.84]; Pâ =â .04) compared to the placebo group. Outcomes assessed in maintenance phase significantly favored the intervention group over placebo as well, histologic remission (RRâ =â 2.39; 95% CI [1.83, 3.11]; Pâ <â .00001), endoscopic improvement (RRâ =â 2.20; 95% CI [1.28, 3.77]; Pâ =â .004), clinical remission (RRâ =â 3.03; 95% CI [1.84, 4.99]; Pâ <â .0001), and clinical response (RRâ =â 1.74; 95% CI [1.25, 2.42]; Pâ =â .001). CONCLUSION: S1PrMs show promising potential for establishing histologic remission, endoscopic improvement, clinical remission, and corticosteroid-free clinical remission. With more studies and clinical trials, these modulators may become a reliable therapeutic choice for UC patients everywhere.